Menu Close

Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by  Zacks Research  from a “get” rating to a “hold” score in a research note issued to financiers on Thursday, records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It focuses on finding and also establishing tiny molecule drug prospects to treat cancer. The Company‘s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts also just recently discussed the business. Noble Financial editioned a “buy” score and issued a $11.00 rate goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also established a “get” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day moving ordinary cost of $2.90 as well as a two-hundred day relocating typical cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an unfavorable net margin of 8,294.27%. The company had earnings of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Throughout the very same quarter in the previous year, the firm published ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly publish -1.18 EPS for the current year.

A number of hedge funds have actually lately bought and sold shares of ONTX. GSA Funding Allies LLP got a new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Funding Management LP acquired a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as various other institutional financiers possess 13.36% of the business’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification and also advancement of oncology therapeutics. It focuses on uncovering and also establishing little particle medication candidates to treat cancer. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a totally free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, check out

This instant news alert was generated by narrative science technology as well as monetary information from Market in order to provide viewers with the fastest and also most accurate coverage. This tale was reviewed by Market’s content team prior to magazine. 



Prior to you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier and also finest executing research experts as well as the stocks they advise to their customers every day. Market has actually recognized the 5 stocks that top experts are quietly whispering to their customers to buy currently before the broader market catches on … and also Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics presently has a “Buy” ranking among experts, premier analysts believe these five stocks are better purchases.